Cargando…
Resistance to Artemisinin Combination Therapies (ACTs): Do Not Forget the Partner Drug!
Artemisinin-based combination therapies (ACTs) have become the mainstay for malaria treatment in almost all malaria endemic settings. Artemisinin derivatives are highly potent and fast acting antimalarials; but they have a short half-life and need to be combined with partner drugs with a longer half...
Autor principal: | Nsanzabana, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473515/ https://www.ncbi.nlm.nih.gov/pubmed/30717149 http://dx.doi.org/10.3390/tropicalmed4010026 |
Ejemplares similares
-
Pre-existing partner-drug resistance to artemisinin combination therapies facilitates the emergence and spread of artemisinin resistance: a consensus modelling study
por: Watson, Oliver J, et al.
Publicado: (2022) -
Partner-Drug Resistance and Population Substructuring of Artemisinin-Resistant Plasmodium falciparum in Cambodia
por: Parobek, Christian M., et al.
Publicado: (2017) -
The influence of pregnancy on the pharmacokinetic properties of artemisinin combination therapy (ACT): a systematic review
por: Burger, Renée J., et al.
Publicado: (2016) -
Protecting future antimalarials from the trap of resistance: Lessons from artemisinin-based combination therapy (ACT) failures
por: Erhunse, Nekpen, et al.
Publicado: (2021) -
Interactions between tafenoquine and artemisinin-combination therapy partner drug in asexual and sexual stage Plasmodium falciparum
por: Kemirembe, Karen, et al.
Publicado: (2017)